Would you consider Amivantamab + Lazertinib combo for first line in EGFR mutated metastatic NSCLC, given the recent ESMO updates?  

I would consider the Ami+Laz combo as one of the options to discuss with patients for 1L EGFR-mutated mets NSCLC, but not necessarily an automatic first choice. The response and survival benefits are to be weighed against the AEs in both their nature and odds of occurrence, in a personalized fashion...